![]() Participation by Novamind shareholders in the future of Numinus: Novamind shareholders will receive Numinus common shares, listed on both the Toronto Stock Exchange (TSX) and the OTC Markets Group’s OTCQX, pursuant to the closing of the Transaction.The acquisition is anticipated to generate C$3 million in annual cost synergies, the majority of which relate to the elimination of duplicative public company expenses and operational systems, further supporting margin enhancement. ![]() The Transaction is expected to be immediately accretive to Numinus’ revenue and gross profit, and, based on forecasts and efficiencies of scale, will shorten the timeline of Numinus’ path to profitability.Accelerates Numinus’ path to profitability:.DEA Schedule 1 licenses for psilocybin research complement Numinus Bioscience’s extensive Health Canada Controlled Drugs & Substances License to possess, produce, assemble, sell, export, deliver, research, and test a wide range of psychedelic drugs and botanical materials, including DMT, ketamine, LSD, MDMA, mescaline, psilocin, psilocybin, ayahuasca and San Pedro. Combines Novamind’s distinguished clinical research site management capabilities with Numinus Bioscience’s bioanalytical laboratory expertise, resulting in a comprehensive clinical research offering.Clinics will also offer family and couples counselling, as well as in-person and virtual group therapy for expanded access to innovative treatments. Services include ketamine-assisted psychotherapy (KAP), Spravato (esketamine), transcranial magnetic stimulation (TMS), talk therapy, group therapy, medication management, psychedelic palliative care and neurological care. Best-in-class service offering with clinics providing a wide range of traditional, innovative and psychedelic mental health treatments that can be appropriately matched to each client’s needs.Increased client programming with complementary service offerings to be shared and expanded across the combined clinic network.Creates an industry-leading North American platform for psychedelic clinics and clinical research.We are excited to join Numinus, a true leader in mental health innovation.” Yaron Conforti, CEO and Co-Founder, Novamind The combined entity is supported with over C$50 million in pro-forma capital and positioned with distinct capabilities to serve a growing and diverse group of stakeholders. and Numinus’ leadership in psychedelic-assisted psychotherapy in Canada creates a best-in-class company. The combination of Novamind’s network of mental health clinics and research sites in the U.S. “This transaction offers significant value for Novamind’s shareholders and provides compelling new opportunities for our employees, patients and research partners. We look forward to welcoming the Novamind team to the Numinus family.” Our combined capabilities will deliver exceptional value for our clients, employees, and shareholders. Nyquvest continued: “We expect this acquisition will significantly bolster our financial performance, growing Numinus’ annual revenue to more than five times our current levels, and driving meaningful margin improvement through identified operating efficiencies.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |